Daunorubicin

About

Therapy type: Chemotherapy

Therapy strategy: Topoisomerase inhibition

Mappings

NCI Thesaurus: Daunorubicin (ncit:C62091)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (1) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.D835Y Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.D835A Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.D835E Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.D835H Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.D835N Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.D835S Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.D835V Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) FLT3 p.I836del Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) CDK12 oncogenic variants Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
EMA (1) CD33 + Acute Myeloid Leukemia Cytarabine, Daunorubicin, Gemtuzumab ozogamicin
EMA (1) FDA (1) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Daunorubicin, Quizartinib